Picard Medical, Inc. - What You Need to Know

Thinking about investing in Picard Medical? Before you commit your hard-earned money, let’s break down what this company actually does and the risks involved. Here is a simple guide to help you understand the latest updates.

1. What does this company do?

Picard Medical is a medical manufacturer that owns SynCardia. They make the only FDA-approved "Total Artificial Heart" (TAH). This device acts as a temporary bridge for patients with end-stage heart failure while they wait for a donor organ. They have helped over 2,100 patients in 27 countries. They are also developing the "Emperor," a next-generation heart designed to improve patient mobility by removing external wires.

2. How do they make money?

They earn money by selling the SynCardia TAH system, which includes the artificial heart and the "Freedom" driver—a portable power unit that lets patients leave the hospital. They also provide training and clinical support for hospital staff. They operate out of Tucson, Arizona, and can produce about 450 hearts per year. They rely on global distributors and partners to meet strict quality standards.

3. The "Institutional Investor" Deal

It is important to know that Picard Medical is not raising new money from the public right now.

In late December 2025, the company borrowed $15 million from an institutional investor, with the option to borrow $35 million more later.

• The Catch: This isn't a standard bank loan. The company gave these investors "warrants," which allow them to buy stock at $2.675 per share. The debt can also be turned into common stock.
• The "Selling Stockholders": This filing registers 17 million shares that these investors may acquire. When these investors sell these shares, the company receives no money. The cash goes directly to the investors.

4. What are the main risks?

• Dilution: When the company issues new shares to pay off debt or satisfy warrants, your ownership percentage drops. Because the company relies on this financing, they may issue many new shares, which could significantly shrink your stake.
• Selling Pressure: These investors hold a large amount of debt and warrants. If they convert these into stock and sell them, the sudden increase in available shares could push the stock price down.
• Legal Protections: The company’s bylaws protect its executives, but the SEC notes that some of these protections are unenforceable under federal law. This limits the company’s ability to cover legal costs for executives in certain disputes.
• Control: The company can issue "blank check" preferred stock. This lets the Board create shares with special voting rights without asking you. Combined with other defenses, this makes it hard for retail investors to influence company decisions.

5. Who’s running the show?

CEO Patrick NJ Schnegelsberg leads the company. You should evaluate his ability to navigate medical regulations and complex manufacturing while managing the company’s heavy debt.

6. Where does it trade?

You can find them on the NYSE American exchange under the ticker "PMI."

Final Thought for Investors: The core of Picard Medical’s business is a specialized, life-saving technology with a proven track record. However, the current financial structure—specifically the heavy reliance on debt that can be converted into stock—creates a significant risk of dilution for everyday shareholders. Before you buy, ask yourself if you are comfortable with the potential for your ownership stake to shrink as the company manages its debt obligations.

Disclaimer: I am an AI, not a financial advisor. Investing in medical tech is volatile. Always read the official "S-1" filing on the SEC website before deciding. Never invest money you cannot afford to lose.